This technical specifications document represents the Food and Drug Administration’s (FDA’s) current thinking on this topic.
Similar Posts
ZoomMax may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use ZoomMax, a product promoted and sold for sexual enhancement on various websites, including www.amazon.com, and possibly in some retail stores.Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805
Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs).Early Alert: Heart Pump Issue from Abiomed
The differential pressure sensor in certain Impella devices may malfunction and cause sensor values to drift.FDA In Brief: FDA Issues Draft Guidance to Encourage Cannabis-Related Clinical Research
FDA has issued draft guidance describing the agency’s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis or cannabis-derived compounds.Torrent Pharmaceuticals Limited – 585255 – 09/04/2024
CGMP/Finished Pharmaceuticals/AdulteratedEmpower Clinic Services LLC dba Empower Pharmacy. Houston, TX. 483 issued 11/14/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/14/2025
Short Title (70 char) Empower Clinic Services LLC dba Empower Pharmacy. Houston, TX. 483 issued 11/14/2025
FEI Number 3021758709
Firm Name Empower Clinic Services LLC dba Empower Pharmacy
Record Type